A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors ...

Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its ...

Rare genetic diseases such as ataxia telangiectasia and cystic fibrosis lack strong commercial incentives, prompting charities to fund early drug research. Innovative approaches are offering renewed ...

Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...

An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...

They live in our houses, drink our water and even sleep in our beds. Cats have become an integral part of many households and share much of our lives. They also share much of their biology with humans ...

Houston Methodist scientists have uncovered an unexpected side of a protein best known for its link to brain diseases. The ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.